Angiogenesis: An update and potential drug approaches (Review)

Maen Abdelrahim, Santhi Konduri, Md Riyaz Basha, Philip A. Philip, Cheryl H. Baker

Research output: Contribution to journalReview articlepeer-review

50 Scopus citations


The therapeutic potential of targeting tumor endothelium and vascular supply is now widely recognized to treat different diseases. One such disease is cancer; where endothelial cells are actively proliferating to support the tumor growth. Solid tumors cannot grow beyond the size of a few millimeters without inducing the proliferation of endothelium and formation of new blood vessels. Hence it is crucial to search for new agents that selectively block tumor blood supply. These include anti-angiogenic molecules, vascular disrupting agents or endothelial disrupting agents. The antiangiogenic molecules such as monoclonal antibodies and tyrosine kinase inhibitors disrupt endothelial cell survival mechanisms and new blood vessel formation, and vascular disrupting agents for instance ligand-directed and small molecules can be used to disrupt the already existing abnormal vasculature that support tumors by targeting their dysmorphic endothelial cells. The recent advances in this area of research have identified a variety of investigational agents which are currently in clinical development at various stages and some of these candidates are already approved in cancer treatment. This report will review some of the recent developments and most significant advances in this field and outline future challenges and directions.

Original languageEnglish (US)
Pages (from-to)5-18
Number of pages14
JournalInternational Journal of Oncology
Issue number1
StatePublished - Jan 2010


  • Anti-angiogenesis
  • Cancer therapy
  • Tumor endothelium
  • Vascular disrupting agents

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Angiogenesis: An update and potential drug approaches (Review)'. Together they form a unique fingerprint.

Cite this